Inequality in the global incidence and prevalence of tuberculosis (TB) and TB/HIV according to the human development index

Batoul Okhovat-Isfahani¹, Saeid Bitara², Mohammad Ali Mansournia¹, Amin Doosti-Irani*³

Received: 27 Feb 2018  Published: 22 May 2019

Abstract

Background: Tuberculosis (TB) is one of the ten leading causes of death, especially in developing countries. We aimed to assess the inequality in the incidence and prevalence of TB and TB/HIV based on the human development index (HDI) globally.

Methods: In this ecological study, the data on the incidence and prevalence of TB, HIV, and TB/HIV co-infection in 168 countries were obtained from the World Health Organization (WHO). The HDI of these countries in 2000, 2005, 2010, and 2015 was also obtained from the United Nations Development Program (UNDP). The concentration index was used to assess the inequality of the incidence and prevalence of TB and TB/HIV based on the HDI globally.

Results: The concentration index for the incidence of TB according to the HDI was -0.32 (95% CI: -0.46, -0.17), -0.36 (95% CI: -0.49, -0.23), -0.37 (95% CI: -0.52, -0.22), and -0.36 (-0.52, -0.21) in 2000, 2005, 2010, and 2015, respectively. The same pattern was observed for the incidence and prevalence of TB/HIV. The results showed that TB and TB/HIV mainly concentrated in countries with a lower HDI.

Conclusion: According to the results of this study, the incidence of TB and TB/HIV and the prevalence of TB/HIV concentrated in the countries with a lower HDI. In addition, inequality in TB and HIV based on the HDI did not change from 2000 to 2015. Therefore, it seems that public health programs, especially in low-income countries, should be revised and the World Health Organization and the United Nations should provide more technical and financial help for these countries.

Keywords: Inequality, Tuberculosis, HIV, Human development index

Conflicts of Interest: None declared
Funding: None

*This work has been published under CC BY-NC-SA 1.0 license.
Copyright© Iran University of Medical Sciences

Cite this article as: Okhovat-Isfahani B, Bitara S, Mansournia MA, Doosti-Irani A. Inequality in the global incidence and prevalence of tuberculosis (TB) and TB/HIV according to the human development index. Med J Islam Repub Iran. 2019 (22 May).33:45. https://doi.org/10.34171/mjiri.33.45

Introduction

Tuberculosis (TB) is one of the serious diseases that can affect all age groups (1). In 2016, 10.4 million people lived with TB, and 1.7 million died due to the disease over the world. TB is one of the 10 important causes of death in the world. More than 95% of deaths from tuberculosis occur in developing countries, of which about 0.4 million are in HIV patients. The risk of tuberculosis among people living with HIV is 20 to 30 times more than HIV negative people. In 2016, about 40% of the deaths in HIV-positive people were due to tuberculosis, and it was estimated that 1.4 million new cases of tuberculosis occurred in HIV-positive people. In 2016, most of the TB cases occurred in Asia (45%) and Africa (25%). India, Indonesia, China, the Philippines, Pakistan, Nigeria, and South Africa are seven

↑What is “already known” in this topic:
The social, environmental and biological risk factors of TB are prevalent among the poor people, and these factors likely contribute to a complex web of poverty-based risk factors of the TB.

—What this article adds:
The results of our study reflect the relationship of HDI as a socioeconomic indicator with the incidence and prevalence of TB and TB/HIV in the world, especially in developing countries. In addition, inequality in TB and HIV based on the HDI did not change from 2000 to 2015.

1 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
3 Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran

Corresponding author: Dr Amin Doosti-Irani, a.doosti@umsha.ac.ir
Global inequality of TB and HIV

countries with the highest priority of new TB cases (1).

TB is preventable and treatable. However, patients may
die if they do not receive proper treatment. According to
the World Health Organization (WHO), TB diagnosis and
treatment saved the lives of 53 million people between
2000 and 2016 (1). To put an end to the TB epidemic is
one of the health targets of the Sustainable Development
Goals By 2030 (1). According to an ecological view, pop-
ulation groups in low-income regions have more health
problems (2). There is an association between socio-
economic inequality and TB and HIV morbidity/mortality
(3, 4). Poverty is one of the determinants of tuberculosis.
There is a linear association between per capita gross do-
meric product (GDP) and the incidence of TB (5). The
level of human development index (HDI) is a strong pre-
dictor of the changes in the incidence of TB during the
time in the countries (6). However, several studies show
the opposite finding (7-9). Many of the social, environ-
mental and biological risk factors of TB, are prevalent in
the poor versus the wealthier people. These factors are
likely contributing to a complex web of poverty-based risk
factors of the TB (10-12). HDI is a three-dimension mea-
sure including life expectancy, education, and income. In
addition, HDI is one of the most important indices which
indicates the level of development in each country (13).

The health dimension of HDI is measured by life expect-
cancy at birth, the education is assessed by the average
number of years of schooling for people over the age of
25, and the income is measured using the gross national
income per capita (14). The HDI shows the distinction
between human well-being and income. Moreover, it can
illustrate a better picture of the country’s development
than does only income (15). The United Nations Devel-
opment Program (UNDP) calculates and reports the HDI
for all countries annually (14).

Assessment of inequality for the incidence and preva-
lence of TB and HIV according to the HDI can aid the
international health organizations in designing better pre-
vention programs to control these infectious diseases
worldwide more efficiently. Based on our knowledge, no
study has assessed inequality in the incidence and preva-
lence of TB and TB/HIV based on the human develop-
ment index; therefore, this study was conducted to inves-
tigate the global inequality for the incidence and preva-
lence of TB and TB/HIV based on the HDI from 2000 to
2015.

Methods

In this global ecological study conducted in January
2018, the inequality for the incidence and prevalence of
TB and HIV based on the HDI was assessed in the world.
The incidence and prevalence of TB, HIV, and TB/HIV
co-infection were obtained from the WHO (16). We also
extracted the HDI of the countries in 2000, 2005, 2010,
and 2015 from the UNDP (17). The incidence and preva-
lence of TB, HIV and TB/HIV were available for 198
countries. HDI was available for 188 countries, and the
incidence, prevalence, and HDI were available just for
168 countries. Finally, we included 168 countries in the
analysis.

In this ecologic study, the prevalence of TB and
TB/HIV in different countries in 2000, 2005, 2010, and
2015 were the outcomes of interest. We also investigated
the trend of inequality between 2000 and 2015.

Concentration index was used for assessment of the in-
equality of TB and TB/HIV based on the HDI. The con-
centration index can be calculated by the following formula:

\[ C = \frac{2}{\mu} \text{cov}(y_i, R_i) \]

Where \( y_i \) and \( R_i \) are the health status of the ith country
and the ith country’s fractional rank in terms of the HDI
status respectively, and \( \text{cov} \) is the weighted covariance
between \( y_i \) and \( R_i \) (18). The concentration index was
weighted using the population size of the countries. The
concentration index ranges between -1 and +1. This index
is commonly used in socioeconomic inequality studies
(10). The negative and positive values of this index indi-
cate the concentration of the health outcome of interest
in the poor and rich population, respectively. In the case
of lack of inequality, the concentration index is zero (11).
The results were reported at 95% confidence interval (CI).
Stata 12 (Stata Corp, College Station, TX, USA) was used
for data analysis.

Results

In this ecological study, we used the data of the inci-
dence and prevalence of TB and TB/HIV as well as the
Niger and Norway had the lowest and highest HDI, re-
spectively.

The highest incidence of TB and TB/HIV was seen in
African regions such as Central African Republic, Leso-
tho, and Swaziland. The lowest incidence of TB and
TB/HIV was seen in Barbados and the United Arab Emi-
rates. The lowest prevalence of TB/HIV was seen in the
United Arab Emirates, Qatar, Jordan, and Tonga in 2000,
2005, 2010, and 2015 respectively, and the highest preva-
lence of TB/HIV was seen in Swaziland.

The concentration index of the incidence of TB based
on the HDI was -0.32 (95% CI: -0.46, -0.17), -0.36 (95%
CI: -0.49, -0.23), -0.37 (95% CI: -0.52, -0.22), and -0.36
(-0.52, -0.21) in 2000, 2005, 2010, and 2015, respectively
(Table 1). The concentration index of the prevalence of
TB/HIV based on the HDI was -0.13 (95% CI: -0.32, 0.08)
and -0.18 (95% CI: -0.33, -0.03) in 2000 and 2015, respec-
tively (Table 1). The concentration index of the incidence
of TB/HIV according to the HDI was -0.53 (95% CI: -0.79,
-0.26) and -0.49 (95% CI: -0.76, -0.22) in 2000 and 2015,
respectively (Table 1).

Table 2 shows the concentration index of the inci-
dence of TB, incidence of TB/HIV, and prevalence of TB/HIV
based on the HDI in WHO regions. The negative values of
the concentration index indicated that tuberculosis was
more concentrated in countries with a lower HDI.

The results showed that the incidence and prevalence
of TB in HIV and the incidence of TB were mainly concen-
trated in countries with a lower HDI. Moreover, the Lo-
renz curve, in all years, showed the concentration of the
incidence and prevalence of TB in HIV-positive people
living in countries with a low HDI. The same results were
Table 1. Concentration indexes for the inequality of TB incidence, TB/HIV incidence, and prevalence of TB/HIV according to the HDI by year

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Year</th>
<th>Concentration index</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lower limit</td>
</tr>
<tr>
<td>Incidence of TB</td>
<td>2000</td>
<td>-0.32</td>
<td>-0.46</td>
</tr>
<tr>
<td></td>
<td>2005</td>
<td>-0.36</td>
<td>-0.49</td>
</tr>
<tr>
<td></td>
<td>2010</td>
<td>-0.37</td>
<td>-0.52</td>
</tr>
<tr>
<td></td>
<td>2015</td>
<td>-0.36</td>
<td>-0.52</td>
</tr>
<tr>
<td>Incidence of TB/HIV</td>
<td>2000</td>
<td>-0.53</td>
<td>-0.79</td>
</tr>
<tr>
<td></td>
<td>2005</td>
<td>-0.58</td>
<td>-0.83</td>
</tr>
<tr>
<td></td>
<td>2010</td>
<td>-0.54</td>
<td>-0.81</td>
</tr>
<tr>
<td></td>
<td>2015</td>
<td>-0.49</td>
<td>-0.76</td>
</tr>
<tr>
<td>Prevalence of TB/HIV</td>
<td>2000</td>
<td>-0.13</td>
<td>-0.33</td>
</tr>
<tr>
<td></td>
<td>2005</td>
<td>-0.19</td>
<td>-0.37</td>
</tr>
<tr>
<td></td>
<td>2010</td>
<td>-0.23</td>
<td>-0.38</td>
</tr>
<tr>
<td></td>
<td>2015</td>
<td>-0.18</td>
<td>-0.33</td>
</tr>
</tbody>
</table>

Table 2. Concentration indices of TB incidence, TB/HIV incidence, and prevalence of TB/HIV according to the HDI by year by WHO regions

<table>
<thead>
<tr>
<th>Outcome</th>
<th>WHO regions</th>
<th>Concentration index (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of TB</td>
<td>Africa</td>
<td>-0.03 (-0.18, 0.12)</td>
</tr>
<tr>
<td></td>
<td>Americas</td>
<td>-0.47 (-0.71, -0.23)</td>
</tr>
<tr>
<td></td>
<td>South-East Asia</td>
<td>0.05 (-0.05, 0.15)</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>-0.39 (-0.57, -0.21)</td>
</tr>
<tr>
<td></td>
<td>Eastern Mediterranean</td>
<td>-0.40 (-0.67, -0.13)</td>
</tr>
<tr>
<td></td>
<td>Western Pacific</td>
<td>-0.01 (-0.29, 0.26)</td>
</tr>
<tr>
<td>TB/HIV incidence</td>
<td>Africa</td>
<td>0.12 (-0.12, 0.35)</td>
</tr>
<tr>
<td></td>
<td>Americas</td>
<td>-0.45 (-0.70, -0.19)</td>
</tr>
<tr>
<td></td>
<td>South-East Asia</td>
<td>-0.02 (-0.25, 0.21)</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>-0.18 (-0.40, 0.04)</td>
</tr>
<tr>
<td></td>
<td>Eastern Mediterranean</td>
<td>-0.43 (-0.83, -0.03)</td>
</tr>
<tr>
<td></td>
<td>Western Pacific</td>
<td>-0.55 (-0.99, -0.11)</td>
</tr>
<tr>
<td>TB/HIV prevalence</td>
<td>Africa</td>
<td>0.07 (-0.13, 0.26)</td>
</tr>
<tr>
<td></td>
<td>Americas</td>
<td>0.07 (-0.09, 0.24)</td>
</tr>
<tr>
<td></td>
<td>South-East Asia</td>
<td>0.003 (-0.24, 0.25)</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
<td>0.30 (0.12, 0.48)</td>
</tr>
<tr>
<td></td>
<td>Eastern Mediterranean</td>
<td>0.25 (-0.23, 0.73)</td>
</tr>
<tr>
<td></td>
<td>Western Pacific</td>
<td>-0.25 (-0.62, 0.11)</td>
</tr>
</tbody>
</table>

Discussion

This ecologic study was conducted to assess the inequality of the incidence and prevalence of tuberculosis based on the HDI. Our results showed that the incidence of TB, incidence of TB/HIV, and prevalence of TB/HIV were concentrated in countries with lower HDI levels. The negative values of concentration index for the TB incidence in the Americas, Europe, and Eastern Mediterranean regions of WHO was statistically significant from the year 2000 to 2015, while these values for other regions seen for the incidence of tuberculosis (Figs. 1-3).

Fig. 1. Concentration curve of TB incidence based on HDI in 2000, 2005, 2010, and 2015

http://mjiri.iums.ac.ir
Med J Islam Repub Iran. 2019 (22 May); 33.45.
Global inequality of TB and HIV

were not statistically significant. A reason may be due to less accurate reported data regarding the incidence of TB and HDI in undeveloped countries, especially in the Africa region. In the case of TB/HIV incidence, the negative values of concentration index for the Americas, Eastern Mediterranean, and Western Pacific regions were statistically significant. In the case of TB/HIV prevalence, the positive value of the concentration index for Europe regions was statistically significant in 2000 and 2005, but these values were not significant in 2010 and 2015. A reason for these positive values may be due to lower mortality of patients with TB/HIV in developed countries.

Our results were also consistent with the results of other studies indicating more concentration of the TB prevalence in countries with a low HDI (19-21). Another study showed inequality in the prevalence of HIV according to the HDI in 2012 (22). There is also a report of inequality in the incidence of cancer based on the HDI globally (23). The reasons for the higher concentration of TB incidence in less developed regions may be living in poor conditions such as food insecurity, inappropriate housing and lack of access to appropriate health care (24).

According to our study, the inequality-adjusted HDI of the incidence of TB decreased from 2000 to 2010 and then increased until 2015. This pattern was consistent with the prevalence of tuberculosis in HIV positive patients. A study showed that the global incidence of tuberculosis was constant from 1990 up to around 2001, and then started to decline until 2012. The rate of decline was 2% between 2011 and 2012. The incidence of TB decreased in all six WHO regions at different rates, ranging from 6.5% per year in the European region to 2% per year in Southeast
Asia and 1% per year in the Eastern Mediterranean (25).

We also found inequality in the incidence of TB according to WHO regions. In most WHO regions, TB and TB/HIV were more concentrated in countries with a lower HDI. According to some studies conducted in the United States and the United Kingdom, poverty, income inequalities, and lack of social capital were important predictors of increased incidence of tuberculosis (26, 27). In addition, our results showed inequality for the incidence of TB in HIV patients based on the HDI. One study showed that TB cases co-infected with HIV were more frequently seen in the African region. Overall, co-infection with HIV was seen in 37% of TB cases in this region, accounting for 75% of TB cases in HIV positive people worldwide (25).

Overall, our results showed that a better socioeconomic status is associated with a lower incidence and prevalence of tuberculosis. The results of this study suggest that although public policies for TB prevention have reduced the disease rate, improvement of other factors such as education and income also have significant impacts (28). Therefore, in developing countries, a control program with a public health approach is required. In fact, every effort should be made to improve the social conditions, such as reduction of the prevalence of communicable diseases.

The first limitation of our study was the use of aggregate data at the country level instead of individual data, which is an important limitation of ecological studies. This bias may occur because an association observed between variables on an aggregated measure does not necessarily indicate an association on an individual level. Therefore, the association between inequality and HDI may have different patterns and interpretations in different countries (29).

Another limitation of this study was regarding the data; we could not obtain the prevalence and incidence of TB and TB/HIV based on the age groups and sex in the countries, so we could not adjust the concentration index based on these variables.

**Conclusion**

Our results reflect the relationship of HDI as a socioeconomic indicator with the incidence and prevalence of TB and TB/HIV in the world, especially in developing countries. In addition, inequality in TB and HIV based on the HDI did not change from 2000 to 2015. Therefore, it seems public health programs, especially in low-income countries, should be revised and the World Health Organization and the United Nations should provide more technical and financial support for these countries.

**Conflict of Interests**

The authors declare that they have no competing interests.

**References**


http://mjiri.iums.ac.ir
Med J Islam Repub Iran. 2019 (22 May); 33.45.
Global inequality of TB and HIV